BioSight
Companies
Foghorn Therapeutics Inc. logo

FHTX

NASDAQCAMBRIDGE, MA
Foghorn Therapeutics Inc.

Foghorn Therapeutics develops drug candidates using its Gene Traffic Control platform, a technology focused on controlling how proteins move within cells. The company's lead program is FHD-909, which is currently in clinical development, and it has a collaboration with Eli Lilly to advance additional programs. Foghorn is in early-stage development and working to obtain FDA regulatory approval for its product candidates.

Price history not yet available for FHTX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar